NASDAQ:SNDX – Page 2

Analysts Viewpoint

Syndax Pharmaceuticals Inc’s recent filing unveils that its Chief Financial Officer Goldan Keith A. acquired Company’s shares for reported $25037.0

Insiders Updates

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or

Stock Earnings

Syndax Pharmaceuticals Inc’s recently made public that its Chief Financial Officer Goldan Keith A. acquired Company’s shares for reported $25037.0

Stock Earnings

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Syndax Pharmaceuticals

Featured

Syndax Pharmaceuticals, Inc. (SNDX), a clinical-stage healthcare company that focuses on an HDAC inhibitor for tumors and specializes in cancer

Tag: NASDAQ:SNDX